More than three dozen pharmaceutical companies raised prices on hundreds of drugs in the U.S. as of Jan. 1. Allergan is setting the pace with increases of nearly 10% on more than two dozen products.
- Many increases are relatively modest, as the industry faces growing public and political pressure over prices. Yet a few are particularly high, including on some generics.
- Overall, the increases, which average 6.3%, continue to exceed inflation. They affect “list prices,” which almost no patient pays because they don’t take into account rebates, discounts and insurance payments.